vs
ACADIA PHARMACEUTICALS INC（ACAD）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
ACADIA PHARMACEUTICALS INC的季度营收约是ROGERS CORP的1.4倍（$284.0M vs $200.5M），ACADIA PHARMACEUTICALS INC净利率更高（96.3% vs 2.2%，领先94.1%），ACADIA PHARMACEUTICALS INC同比增速更快（9.4% vs 5.2%），过去两年ACADIA PHARMACEUTICALS INC的营收复合增速更高（17.5% vs -3.3%）
阿卡迪亚制药是一家总部位于美国加利福尼亚州圣地亚哥德尔马地区的生物制药企业，专注于中枢神经系统相关疾病治疗药物的研发、生产与商业化，致力于为全球患者提供创新的临床治疗方案。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
ACAD vs ROG — 直观对比
营收规模更大
ACAD
是对方的1.4倍
$200.5M
营收增速更快
ACAD
高出4.1%
5.2%
净利率更高
ACAD
高出94.1%
2.2%
两年增速更快
ACAD
近两年复合增速
-3.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $284.0M | $200.5M |
| 净利润 | $273.6M | $4.5M |
| 毛利率 | 90.8% | 32.2% |
| 营业利润率 | 6.1% | — |
| 净利率 | 96.3% | 2.2% |
| 营收同比 | 9.4% | 5.2% |
| 净利润同比 | 90.3% | 421.4% |
| 每股收益（稀释后） | $1.61 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACADROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $284.0M | $201.5M | ||
| Q3 25 | $278.6M | $216.0M | ||
| Q2 25 | $264.6M | $202.8M | ||
| Q1 25 | $244.3M | $190.5M | ||
| Q4 24 | $259.6M | $192.2M | ||
| Q3 24 | $250.4M | $210.3M | ||
| Q2 24 | $242.0M | $214.2M |
净利润ACADROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | $273.6M | $4.6M | ||
| Q3 25 | $71.8M | $8.6M | ||
| Q2 25 | $26.7M | $-73.6M | ||
| Q1 25 | $19.0M | $-1.4M | ||
| Q4 24 | $143.7M | $-500.0K | ||
| Q3 24 | $32.8M | $10.7M | ||
| Q2 24 | $33.4M | $8.1M |
毛利率ACADROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | 90.8% | 31.5% | ||
| Q3 25 | 92.2% | 33.5% | ||
| Q2 25 | 92.2% | 31.6% | ||
| Q1 25 | 91.7% | 29.9% | ||
| Q4 24 | 91.6% | 32.1% | ||
| Q3 24 | 92.5% | 35.2% | ||
| Q2 24 | 92.5% | 34.1% |
营业利润率ACADROG
| Q1 26 | — | — | ||
| Q4 25 | 6.1% | 3.5% | ||
| Q3 25 | 12.8% | 7.3% | ||
| Q2 25 | 12.2% | -33.3% | ||
| Q1 25 | 7.9% | -0.2% | ||
| Q4 24 | 59.1% | -6.6% | ||
| Q3 24 | 12.6% | 6.9% | ||
| Q2 24 | 12.6% | 5.3% |
净利率ACADROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | 96.3% | 2.3% | ||
| Q3 25 | 25.8% | 4.0% | ||
| Q2 25 | 10.1% | -36.3% | ||
| Q1 25 | 7.8% | -0.7% | ||
| Q4 24 | 55.4% | -0.3% | ||
| Q3 24 | 13.1% | 5.1% | ||
| Q2 24 | 13.8% | 3.8% |
每股收益（稀释后）ACADROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | $1.61 | $0.20 | ||
| Q3 25 | $0.42 | $0.48 | ||
| Q2 25 | $0.16 | $-4.00 | ||
| Q1 25 | $0.11 | $-0.08 | ||
| Q4 24 | $0.86 | $-0.04 | ||
| Q3 24 | $0.20 | $0.58 | ||
| Q2 24 | $0.20 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $177.7M | $195.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $1.2B |
| 总资产 | $1.6B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACADROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $177.7M | $197.0M | ||
| Q3 25 | $258.0M | $167.8M | ||
| Q2 25 | $253.6M | $157.2M | ||
| Q1 25 | $217.7M | $175.6M | ||
| Q4 24 | $319.6M | $159.8M | ||
| Q3 24 | $155.1M | $146.4M | ||
| Q2 24 | $177.1M | $119.9M |
股东权益ACADROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.2B | $1.2B | ||
| Q3 25 | $917.3M | $1.2B | ||
| Q2 25 | $822.4M | $1.2B | ||
| Q1 25 | $765.2M | $1.3B | ||
| Q4 24 | $732.8M | $1.3B | ||
| Q3 24 | $577.2M | $1.3B | ||
| Q2 24 | $516.7M | $1.3B |
总资产ACADROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.6B | $1.4B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $1.1B | $1.5B | ||
| Q4 24 | $1.2B | $1.5B | ||
| Q3 24 | $976.9M | $1.5B | ||
| Q2 24 | $914.1M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-48.7M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | — | $1.1M |
| 自由现金流率自由现金流/营收 | — | 0.5% |
| 资本支出强度资本支出/营收 | — | 2.3% |
| 现金转化率经营现金流/净利润 | -0.18× | 1.29× |
| 过去12个月自由现金流最近4个季度 | — | $70.1M |
8季度趋势，按日历期对齐
经营现金流ACADROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $-48.7M | $46.9M | ||
| Q3 25 | $74.3M | $28.9M | ||
| Q2 25 | $64.0M | $13.7M | ||
| Q1 25 | $20.3M | $11.7M | ||
| Q4 24 | $40.4M | $33.7M | ||
| Q3 24 | $63.2M | $42.4M | ||
| Q2 24 | $25.0M | $22.9M |
自由现金流ACADROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | — | $42.2M | ||
| Q3 25 | $73.9M | $21.2M | ||
| Q2 25 | — | $5.6M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $18.3M | ||
| Q3 24 | $63.2M | $25.2M | ||
| Q2 24 | — | $8.8M |
自由现金流率ACADROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | — | 20.9% | ||
| Q3 25 | 26.5% | 9.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 9.5% | ||
| Q3 24 | 25.2% | 12.0% | ||
| Q2 24 | — | 4.1% |
资本支出强度ACADROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | — | 2.3% | ||
| Q3 25 | 0.1% | 3.6% | ||
| Q2 25 | — | 4.0% | ||
| Q1 25 | — | 5.0% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | 0.0% | 8.2% | ||
| Q2 24 | — | 6.6% |
现金转化率ACADROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | -0.18× | 10.20× | ||
| Q3 25 | 1.03× | 3.36× | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | 3.96× | ||
| Q2 24 | 0.75× | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
ROG
暂无分部数据
